Crossmark

Patient-specific and healthcare real-world costs of atrial fibrillation in individuals treated with direct oral anticoagulant agents or warfarin

Published Online: 2021-12-03

Published Print: 2021-12

Authors

Pyykönen, Mikko

Linna, Miika

Tykkyläinen, Markku

Delmelle, Eric

Laatikainen, Tiina
License Information

Text and Data Mining valid from 2021-12-01

Version of Record valid from 2021-12-03
More Information

Article History

Received: 17 March 2021

Accepted: 1 October 2021

First Online: 3 December 2021

Declarations

:

: Use of the data in this research was approved by the Ethics Committee of the North Savo Hospital District. The approval for data use was achieved from joint municipal authority for North Karelia social and health services administering the patient registers. The data was anonymised before its use.The Finnish legislation do not require informed consent for register-based research, as the study is solely based on registers (involving no contact with the study subjects) and the study is considered to be of public health importance. The data used in this study was anonymised before its use.

: Not applicable.

: Pyykönen, M. Linna, M. Tykkyläinen, M. Delmelle, E. and T. Laatikainen declare no competing interests.

Document is current